Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Mast launches new indirect carbapenemase testing solution

Mast launches new indirect carbapenemase testing solution

22nd May 2017

Mast has announced the launch of Mast ICT, the latest addition to its Mastdiscs ID range of testing solutions.

Based on the principles of the indirect carbapenemase test, Mast ICT is a paper test device for use in the screening of OXA, KPC, NDM, IMP and VIM enzymes, and is suitable for use with acinetobacter, pseudomonas spp and enterobacteriaceae.

The level of carbapenem resistance amongst Gram-negative bacteria caused by carbapenemases is a major public health concern at present, with the overuse of antibiotics leading to the development of untreatable superbugs.

Mast ICT uses a cell permeabilising agent to release the carbapenemase enzyme from carbapenemase-producing-organisms to hydrolyse indicator antibiotics in the test system, allowing a normally carbapenem-susceptible reporter organism to grow where the antibiotic has been hydrolysed.

This results in a distorted zone of inhibition, meaning that if the test organism produces no carbapenemase, the reporter organism will form a regular, circular zone of inhibition around the indicator tip.

With this testing solution, results can be interpreted through simple observation, while the convenient format of the test means it can fit into a range of different laboratory workflows.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801836111-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.